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C
ongenital heart defects (CHDs) are the most common
type of birth defect, affecting 1% of births per year.
1
Although survival has been improving over time, there remain
numerous gaps in the understanding of the public health
impact of CHDs across the lifespan. Recognizing that there
was “a lack of rigorous epidemiological and longitudinal data
on individuals of all ages with congenital heart disease,” the
US Congress provided funding through the Appropriations Act
of 2012 to the US Centers for Disease Control and Prevention
(CDC) to investigate the gaps in understanding of the public
health impact of CHDs.
2 Given the broad array of possible
topics to address with limited resources, the CDC invited
experts to a meeting on September 10–11, 2012, to seek
individual input on the major gaps in the understanding of
CHDs and to suggest public health strategies to address
those gaps.
Fifty experts attended the meeting representing diverse
specialties and perspectives including medical content
(CHDs), methods (public health strategies), and personal
experience. The group included persons and stakeholders
from varied disciplines (physicians, surgeons, epidemiologists,
public health ofﬁcials, advocates, and patients) with a broad
representation of public health, professional, and CHD
advocacy organizations (the full list of experts is included in
the Acknowledgments section).
Prior to the meeting, participants received background
information to lay the foundation for the meeting. Participants
were asked to attend 1 of 2 live webinars hosted by the CDC
to outline the public health framework for congenital heart
defects. Participants also received articles covering key topics
in public health and congenital heart defects for review on
their own prior to the meeting.
3–6 Finally, at the initiation of
the meeting, background presentations were delivered on the
current state of knowledge for each of the 4 key areas:
epidemiology, health services, long-term morbidity/mortality,
and long-term psychosocial and neurodevelopmental outcomes.
For the major activity of the conference, invitees partic-
ipated in 1 of 4 focus groups centered on 1 of those key
areas. Each group was charged with 3 tasks: (1) identifying
the key gaps in public health for CHDs, (2) brainstorming
potential strategies to address those gaps, and (3) suggesting
a prioritization of the identiﬁed gaps and strategies based on
their potential impact and feasibility. The results of each
group, with notable overlaps, were discussed by the full panel
of participants to help guide an overall list of suggested major
focus areas. After a large group discussion of the 32 gaps
identiﬁed, the gaps identiﬁed as prioritized, in no particular
order, included prevalence of CHDs across the lifespan, risk
factors for development of CHDs, long-term outcomes for
persons with CHDs, health services delivery for persons with
CHDs, and public awareness of the burden and impact of
CHDs. As outlined in Table 1, we have synthesized the
prioritized gaps and their accompanying strategies into a
public health science agenda for CHDs.
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SPECIAL REPORTWhat is Public Health Research/Surveillance?
In developing a public health science agenda for CHDs, it is
important to ﬁrst deﬁne the scope of “public health” and its
associated scientiﬁc activities. Public health focuses on the
health of the population rather than the health of an
individual; thus public health efforts are typically prevention
activities targeting a population to reduce morbidity and
mortality on a population level.
7 A public health science
agenda is a cycle of surveillance, research, and prevention
activities (Figure).
The cycle’s cornerstone is public health surveillance, which
is a systematic process to monitor health through ongoing
collection, analysis, interpretation, and dissemination of data
to improve health.
8 Population-based surveillance data can be
used to address key research questions about: the magnitude
of the health problem, the natural history of the condition, the
distribution of the condition across geographic regions or by
speciﬁc characteristics (eg, maternal race or ethnicity), any
changes in prevalence over time that might be due to
changing exposures or changing technology for diagnosis,
and/or the impact of prevention activities. Public health
surveillance also serves as the source of population-based
cases for additional public health research studies and is
useful in planning for future resource needs.
Public health research is designed to create generalizable
knowledge that will apply to populations beyond the imme-
diate study population being evaluated. Focused public health
Table 1. Major Gaps and Strategies for a Public Health Science Agenda for Congenital Heart Defects
Key Gaps
Strategies to Address Gaps
High Impact,
High Feasibility High Impact, Moderate Feasibility Moderate Impact, High Feasibility
Prevalence of congenital heart defects across the
lifespan
Existing databases and
electronic records
Population based cohorts
Ongoing public health
surveillance efforts
Voluntary registries
Mathematical modeling
Risk factors for development of congenital
heart defects
Social determinants of
health
Modifiable risk factors Genetic associations
Primary prevention strategies
Long-term outcomes for persons with congenital
heart defects
Linkage of databases
Longitudinal surveillance
and research
Meaningful outcomes measures
Health services delivery for persons with congenital
heart defects
Access to appropriate care
Continuation of care from
adolescence to adulthood
Costs of care
Quality of care
Public awareness of the burden and impact of
congenital heart defects
Public awareness
campaign
Educational materials
Monitor prevalence of CHDs and associated 
sequelae in population to determine impact of 
prevention and suggest avenues for future research
Surveillance
Identify modifiable causal factors for CHDs and 
factors that impact the longer term outcome for 
those with CHDs
Research
Implement efforts to reduce exposures to causal 
factors or employ strategies to improve the long 
term health of those with CHDs
Prevention
Figure. Public health cycle for congenital heart defects (CHDs).
DOI: 10.1161/JAHA.113.000256 Journal of the American Heart Association 2
Public Health Science Agenda for CHDs Oster et al
S
P
E
C
I
A
L
R
E
P
O
R
Tresearch on CHDs includes speciﬁc studies to identify risk
factors as well as studies of the prognosis and longer-term
outcomes for those affected. A typical risk factor study of
CHDs might assess maternal exposures during pregnancy to
identify modiﬁable factors that can increase the risk of CHDs
such as maternal smoking, maternal diabetes, or maternal
medication use in early pregnancy (eg, opioid analgesics).
Public health research outcomes studies also seek to identify
factors such as optimal timing of medical care that can
potentially improve the outcomes of those with CHDs. This
includes health economic studies that assess the healthcare
and nonhealthcare resources used by those with CHDs.
Modiﬁable factors identiﬁed through public health research
can guide prevention activities. Primary prevention strategies
attempt to modify risk factors to decrease the occurrence of
CHDs, while secondary prevention strategies aim to improve
the lives of people with CHDs. The public health cycle then
loops back into surveillance to gauge the effectiveness of
prevention strategies.
The convened conference identiﬁed 5 key areas for a CHD
public health science agenda: prevalence of CHDs across the
lifespan, risk factors for development of CHDs, long-term
outcomes for persons with CHDs, health services delivery for
persons with CHDs, and public awareness of the burden and
impact of CHDs.
Prevalence of Congenital Heart Defects
Across the Lifespan
While there are relatively robust estimates of CHD prevalence
detectable at birth, there are no population-based data on
the prevalence beyond early childhood in the United States.
1,9
The prevalence of CHDs across the lifespan is impacted by the
mortality of each birth cohort and by relatively late diagnoses
of CHDs not apparent during infancy. Robust estimates of CHD
prevalence across the lifespan (newborns, children, adoles-
cents, adults) would allow better characterization of the
disease burden including morbidity, mortality, healthcare use
and costs, nonhealthcare costs associated with CHDs, disabil-
ity, and the potential longer-term impact of CHDs on education
and employment. In the following section we review some of
the established methods for estimation of disease states
across the lifespan. Some combination of these methods
applied to CHDs would provide a more accurate characteriza-
tion of the burden of the disease across the lifespan.
Ongoing Public Health Surveillance Efforts
When the 50 states, the District of Columbia, and Puerto Rico
were surveyed in November 2011, 43 of the 52 respondents
reported having a birth defects surveillance program that
obtained data on CHDs.
10 Of these 43 programs, 41 reported
data to the National Birth Defects Prevention Network for the
December 2012 annual report.
11 Most programs ascertain
infants diagnosed with a CHD before 1 year of age, and some
included diagnoses in the ﬁrst few years of life. Such
ascertainment is useful for estimating the prevalence of
CHDs at birth. Some longstanding surveillance programs
estimate prevalence and survival of those infants with certain
conditions (eg, Down syndrome, spina biﬁda) in childhood and
adolescence by linking birth defects surveillance data to state
death records and the national death index.
12,13 Strengths of
these birth defect surveillance programs include being
population-based and not being biased by issues of access
or referral patterns. Limitations include the lack of information
beyond infancy and variations in case deﬁnition, data sources,
and ascertainment methodology (eg, active versus passive
ascertainment).
9,14
Population-Based Cohorts
Population-based longitudinal cohorts of persons with CHDs
at any age could be established in a deﬁned source population
and then followed on a periodic basis such as with annual
data abstraction of medical records. Although ﬁnancially and
logistically challenging, such a method would offer robust,
population-based estimates of the changing prevalence of
CHDs and their associated morbidities. This approach has
been used to establish cohorts for Duchenne/Becker muscular
dystrophy and hemoglobinopathies.
15,16
Existing Databases and Electronic Records
Leveraging existing databases might provide an opportunity to
estimate the prevalence of CHDs across the lifespan without
undertaking resource-intensive data collection. To create a
population-based estimate, the source population would need
to be clearly deﬁned, and multiple data sources would
maximize completeness of case ascertainment. Some critical
data sources for such an endeavor might include vital records
(birth and death records), CHD specialty clinic records,
hospital discharge records, and insurance databases (public
and private). The expanded use of electronic health records
may provide opportunities to search existing data and make
accurate linkages between data sources.
17 Linkage and
deduplication of these various sources would improve
case-ﬁnding and allow a reasonable population-based esti-
mate of persons with CHDs across the lifespan who are
currently seeking care for their CHD or who die as a result of
their CHD. Unfortunately, this strategy might be limited by the
need for a CHD diagnosis to be speciﬁcally noted in a medical
record. Variations of this approach are being piloted in 3 sites
recently funded by CDC to conduct CHD surveillance among
adolescents and/or adults.
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Persons with CHDs and/or their health care providers can log
important diagnosis and descriptive information through
voluntary registries. Registries (with or without personally
identifying information) serve as a repository of people who
potentially can be approached for outcomes research and
longitudinal follow-up. However, self-identifying voluntary
registries may not be representative of all persons with CHDs
in the source population; enrollees may differ in terms of
educational level, income, race/ethnicity, disease severity,
access to healthcare, and insurance status. Studies from
patient registries for other conditions (eg, cystic ﬁbrosis) have
potential selection bias with the registry overenrolling at 1
extreme of the disease spectrum.
18 However, despite their
signiﬁcant limitations of representativeness, this type of
registry can provide a relatively low-resource approach to
capturing some longitudinal data on a hopefully diverse
sample of persons with CHDs.
Mathematical Modeling
Given the current lack of data to directly estimate the
prevalence of CHDs across the lifespan in the United States,
mathematical modeling has been used to apply estimates
from available sources (ie, population-based data from
Quebec) to the US population in order to estimate the
number of persons living with CHDs in each age cohort.
19,20
Based on this modeling, the number of people in the United
States with a CHD at any age was estimated to be at least 2
million, with at least half of these individuals being adults
(≥18 years). As more current data become available, these
estimates can be updated and informed by other data sources
to improve their accuracy.
Risk Factors for Development of Congenital
Heart Defects
While the causes of most CHDs are unknown, they are likely
multifactorial in origin.
4,21 Although the available evidence on
risk factors to guide effective primary prevention strategies is
limited or inconsistent,
4 there are some established risk
factors for CHDs and prevention strategies are in place. Much
like an iceberg, however, it is likely that there are more
unseen than seen causes of CHDs. Future research to delve
deeper into causes is needed.
Modiﬁable Risk Factors
Maternal conditions such as diabetes, obesity, phenylketon-
uria, and rubella infection are established risk factors for
CHDs.
4,22–24 Associations also have been identiﬁed between
CHDs and maternal periconceptional medication use such as
retinoic acid, valproate, phenytoin, and opioid analgesics.
4,25
Other medications or conditions also may be associated with
CHDs, but it is difﬁcult to differentiate the effect of the
condition from the medication used to treat the condition.
4
There is also some evidence for association between CHDs
and environmental factors such as maternal smoking and
exposure to organic solvents.
4,26
Despite clear documentation of these known risk factors,
there is still a gap in identifying factors which, when modiﬁed,
will have a large, demonstrable, public health impact on the
prevalence of CHDs. Population-based case-control studies,
such as the National Birth Defects Prevention Study (NBDPS),
are 1 approach to assess the association of exposures with
CHDs, and efforts should continue to analyze existing
case-control data. However, differences in study methodology
and resultant risk make comparisons across studies difﬁcult.
The impact of future work could be magniﬁed by increased
focus on standardizing case deﬁnitions and nomenclature,
improving the quality of exposure data (eg, complement
self-report with medical records data or biological samples),
and exploring other innovative methods to gather data
(eg, through patient support groups, biological modeling).
Genetic Associations
Approximately 15% to 20% of CHDs have been linked to
known genetic disorders such as Down syndrome, Turner
syndrome, and 22q11.2 deletion.
27 Nevertheless, estimates
vary widely as the ﬁeld of cardiovascular genetics rapidly
evolves with new technology and potential associations.
Knowledge of a genetic abnormality may indicate other organ
involvement, prognostic factors, and reproductive risks.
21
Population-based research could help identify genotype
associations and assess the effects of gene-environment
interactions on CHD development and determinants of health
for those with CHDs.
Social Determinants of Health
Little is known about the distribution of CHDs stratiﬁed by
factors such as race-ethnicity, residence, sex, or insurance/
payor status and how these factors impact CHDs across the
lifespan. Improved understanding of demographic,
geographic, behavioral, and social determinants could guide
targeted prevention strategies. For example, to improve
prevention of neural tube defects in speciﬁc populations,
researchers have evaluated the potential impact that corn
masa ﬂour fortiﬁcation could have on folic acid intake.
28 One
strategy to explore social determinants of CHDs would be to
analyze current databases or link existing databases with
census data or geocoding. Analyzing health disparities across
DOI: 10.1161/JAHA.113.000256 Journal of the American Heart Association 4
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prevention efforts.
Primary Prevention Strategies
Evidence on modiﬁable risk factors and determinants of
health should be translated to expand public health preven-
tion interventions. Work is needed to identify additional
simple, reasonable, and effective public health prevention
efforts for CHDs, and to assess their impact. For instance, all
women of childbearing age should consume sufﬁcient folic
acid by taking a multivitamin containing folic acid, be
screened for and control chronic conditions such as diabetes,
and keep immunizations current. Furthermore, during preg-
nancy, women should discuss medication use with their
doctor for potential teratogens, stop or avoid smoking and
alcohol use, and avoid exposures to heavy metals, pesticides,
and organic solvents.
4 Further research is needed to assess
to what extent are these guidelines being followed and the
impact of these prevention strategies.
Long-Term Outcomes for Persons With CHDs
With advances in medical and surgical care of CHDs over
recent decades, it is expected that the large majority of
patients with CHDs will live well into adulthood.
19,29 While
survival has been extended for many conditions, the morbid-
ity that accompanies this survival has not been well
described on a population level. Prior large population efforts
have investigated epidemiology among infants with CHD,
30,31
and “natural history” studies on less complex lesions focused
mostly on surgical and cardiac outcomes.
32–35 What has
been missing from previous studies is an evaluation of not
only the superimposed conditions of adulthood such as
hypertension, diabetes, and sleep apnea, but also the
potential for the effects of CHDs (and its associated
interventions) on the health of other organ systems, including
liver, renal, and lung disease.
36–38 Addressing the lack of
knowledge regarding the long-term physical, neurodevelop-
mental, psychosocial, and reproductive outcomes of the
aging CHD population is an important area with the potential
of having a high impact on improving the public health for
persons with CHDs.
Linkage of Databases
One approach is to leverage and link currently existing
databases and registries. A clear strength of this strategy is
the wealth of data already being collected by a number of
different databases and registries encompassing many
aspects of overall cardiac care, including, but not limited to,
the various clinical,
39 surgical,
40 critical care,
41 anesthesia,
42
and administrative databases
43 (Table 2). Rather than creat-
ing new databases, this strategy aims to foster collaborative
opportunities for learning. Furthermore, while there are no
population-based databases that are individually tracking
long-term outcomes, merging information across databases
over time may be able to provide valuable long-term outcomes
data. A notable obstacle to this strategy is the absence of a
global unique identiﬁer.
44,45 Without such an identiﬁer, this
strategy will be limited by the ability to merge databases
through probabilistic matching or other methods. The use of a
global unique identiﬁer has been instrumental in linking
databases in other chronic conditions such as autism.
45
Therefore, the working group collectively recommends the
establishment of a global unique identiﬁer to facilitate
effective global database linkage to allow tracking of long-
term outcomes for CHD patients.
Another limitation to database linkage is the inpatient bias
of most existing databases, thus not allowing the capture of
data in the outpatient or even nonclinical settings. This
obstacle could be navigated by encouraging and fostering the
creation and implementation of databases that track the
outpatient experiences of persons with CHDs. Finally, efforts
to link and compare databases may also be limited by
variations in coding, nomenclature, and classiﬁcation of
CHDs. Administrative codes do not clearly distinguish some
CHD phenotypes, which can have important etiologic differ-
ences.
46 Efforts to standardize CHD deﬁnitions and coding
should be supported.
Although this strategy has challenging obstacles, they are
not necessarily insurmountable and the potential positive
impact is great. In addition to learning about patient-level
outcomes for persons with CHDs, successful linkage of these
databases may help identify benchmarks for care and inform
screening and prevention efforts.
Longitudinal Surveillance and Research
An alternative to the linkage of existing databases is longitu-
dinal surveillance of persons with CHD utilizing periodic
surveys or medical abstraction. Longitudinal surveillance could
provide information on a variety of outcomes—medical (eg,
heart and other organs), neurodevelopmental (eg, special
education needs and cognitive capacity), reproductive (eg,
sexual/contraceptive practices, pregnancy, family planning,
and heritability for offspring), and psychosocial (eg, employ-
ability and perceived quality of life). Once the incidence,
prevalence, risk factors, and disparities of various outcomes
are known, public health intervention efforts to change these
outcomes can be developed. While such a study would be
impactful on many levels, the feasibility is challenging given
the estimated resources required. Multicenter and/or multia-
gency collaboration may help overcome this obstacle.
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Finally, no matter what strategy is employed to assess
long-term outcomes, it is important to determine what
measures are most meaningful and relevant for the CHD
population. While mortality is one outcome of interest,
outcomes such as disability-adjusted life expectancy or
quality-of-life–adjusted life expectancy could allow compari-
son of CHDs to other chronic illnesses. Furthermore,
improved metrics aimed at evaluating other medical or
psychosocial outcomes would aid in building a comprehensive
understanding of the long-term effects of CHDs. Although
challenging, development of such key metrics will generate
substantial impact by describing lifetime impact in
easily understandable and measureable terms. The input of
CHD patients and their families will be invaluable in the
development of meaningful metrics of long-term outcomes.
Health Services Delivery for Persons With
Congenital Heart Defects
Understanding and implementing optimal health services in a
systematic manner presents an opportunity for improving
health outcomes for patients with CHDs. By ensuring access
to appropriate care, transitioning care from adolescence to
adulthood, quantifying the costs of care, and improving the
quality of care delivered, the overall public health of persons
with CHDs can be optimized. As discussed above, compre-
hensive tracking and assessment of persons living with CHDs
is essential to the development of the most efﬁcacious
treatment plans, but these treatment plans can only be
effective at the population level if delivery of health services is
pervasive and efﬁcient.
Access to Appropriate Care
Access to appropriate care is of paramount importance for
those with CHDs. Barriers to receiving care include lack of
education, lack of adequate insurance, unemployment, and
lack of proximity to a specialized care center.
47 A key issue for
the public health science agenda for persons living with CHDs
is to understand and overcome the challenges in access to
care for all ages. The Patient Protection and Affordable Care
Act of 2010, Pub. L. 111-148 will improve access to health
insurance and health care for millions of Americans, and
therefore is likely to improve access for many people with
CHDs. However, there might still be other challenges for this
population related to healthcare access. For example, there
may be a growing gap between the demand for providers
trained in caring for adults with CHDs and the supply of those
providers. The recent establishment of Adult Congenital Heart
Table 2. Select Databases and Registries for Studying
Outcomes for Persons With Congenital Heart Defects in the
United States
Birth Defects Surveillance Programs (multiple)
Centers for Medicare and Medicaid Services (CMMS)
Congenital Cardiac Catheterization Project on Outcomes (C3PO)
Congenital Cardiovascular Interventional Study Consortium (CCISC)
Congenital Database of the Society of Thoracic Surgeons (STS)
Congenital Evaluation, Reporting, and Tracking Endeavor (CONGENERATE)
(Canada and US)
Congenital Heart Surgeons’ Society (CHSS) Research Databases
Early Intervention Databases (multiple)
Health Care Utilization Project (HCUP)—Kids’ Inpatient Database (KID)
Health Care Utilization Project (HCUP)—Nationwide Inpatient Sample (NIS)
Health Care Utilization Project (HCUP)—State Inpatient Databases (SID)
HMO Research Network (HMORN)
Improving Pediatric and Adult Congenital Treatment (IMPACT) of the
National Cardiovascular Data Registry of the American College of
Cardiology Foundation (ACCF) and the Society for Cardiovascular
Angiography and Interventions (SCAI)
Joint Congenital Cardiac Anesthesia Society—Society of Thoracic
Surgeons Database
Joint Council on Congenital Heart Disease (JCCHD) National Quality
Improvement Initiative
MarketScan
  Research Databases
Mid-Atlantic Group of Interventional Cardiology (MAGIC) Catheterization
Outcomes Project
National Association of Children’s Hospitals and Related Institutions
(NACHRI) Case Mix Comparative Data Program (CMCDP)
National Birth Defects Prevention Network (NBDPN)
National Birth Defects Prevention Study (NBDPS)
National Hospital Care Survey (NHCS)
National Hospital Discharge Survey (NHDS)
National Survey on Children with Special Healthcare Needs (NS-CSHCN)
Pediatric Cardiac Care Consortium (PCCC)
Pediatric Cardiac Genomics Consortium (PCGC)
Pediatric Heart Network (PHN)
Pediatric Hospital Information System (PHIS)
Pediatric Hospital Information System—Society of Thoracic Surgeons
(PHIS-_STS) Linked Dataset
Slone Epidemiology Center’s Pregnancy Health Interview Study/Birth
Defects Study, Boston University
Special Education and other educational Databases (multiple)
State All-Payor Claims Databases (multiple)
State Hospital Discharge Databases (multiple)
Virtual Pediatric Intensive Care Unit Performance System (VPS)
Vital Records
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American Board of Medical Specialties is a critical ﬁrst step in
addressing this gap, but it is not the sole solution. Notable
barriers to increasing the number of subspecialty providers
include a lack of appropriate training centers, excess length of
time for additional training, and the existing debt burden of
trainees. Another essential needed change is the enhance-
ment of general adult cardiologist training in the care of adults
with less complex CHDs. This approach will allow for more
accessible care for most CHD patients while leaving more time
for ACHD specialists to care for the most complicated cases.
Continuation of Care From Adolescence to
Adulthood
It is well documented that many adolescents and young
adults with CHD are either lost to follow-up or are not
receiving recommended care.
48,49 Identifying CHD patients
who fail to maintain care as they transition to adulthood and
facilitating the transition process will improve the continuity
of care and ultimately optimize quality of life and life
expectancy.
50 The underlying cause of poor continuation of
care is likely multifactorial, including lack of ACHD provider
availability, lack of patient and parent awareness of the
severity of their illness and resulting need for lifelong care,
and lack of consistent processes for transition and transfer
of care. In locations where appropriately trained adult
providers are available, developing lifelong centers of care
that foster close collaboration between pediatric and adult
providers may help facilitate seamless transition and full
physician knowledge of patient history in a setting familiar to
the patient. Regionalization of specialty center care may
support such an approach. With the diversity of care models
across the United States no one strategy is likely to be
optimal for all locations and/or patients. Therefore, extra-
mural grants aimed at the development of lifespan-focused
treatment centers for CHDs could support pilot demonstra-
tion projects that may be reproduced and expanded to other
regions.
Costs of Care
In an environment of limited resources and rapidly rising
costs, delivering value in health care has become a key
focus throughout our healthcare system.
51 There is relatively
little known about the costs of care for children with CHDs,
and even less known for adults. Not knowing or realizing the
value of healthcare interventions can impede innovation and
hamper ultimate care and outcomes. However, by using
various national administrative and clinical datasets, one can
begin to estimate the cost of care for persons with CHDs.
These cost estimates can draw attention to the health needs
of CHD patients. Involving health economists might assist
with identiﬁng opportunities for improving CHD resource
use.
Quality of Care
It is important to ensure that proven, effective, value-based
strategies are implemented appropriately and consistently.
For example, there is substantial variation in initial perioper-
ative management of patients with single ventricle physiol-
ogy.
52 Such variation may lead to differences in health
outcomes and costs.
3 Minimizing practice variation may
improve health outcomes and efﬁciency. A quality improve-
ment initiative is one approach to reducing variation and
optimizing medical practices. Quality improvement initiatives
are continuous cycles of using data to identify, develop, and
implement strategies to change and improve practices.
Strategies for quality improvement have the potential for
great impact because they help to limit unnecessary variabil-
ity, reduce costs, and improve health outcomes on a grand
scale. Unfortunately, there are also formidable barriers to
improving the quality of care, most notably a lack of sufﬁcient
and reliable evidence upon which to base guidelines. In the
absence of such evidence, expert opinion and experience
must serve as the basis for quality improvement efforts.
Strategies to collect better evidence, therefore, are imperative
and will depend on the building blocks offered by better
lifespan tracking of CHD patients, as discussed above. An
example of such an effort is the National Pediatric Cardiology
Quality Improvement Collaborative of the Joint Council on
Congenital Heart Disease,
53 a multicenter collaborative to
prospectively collect data and track outcomes on infants with
single ventricle physiology. Simply identifying the key strat-
egies to improve quality will not be enough; these efforts must
be widely disseminated, adopted, and tracked. Appropriate
incentives and penalties—ﬁnancial or otherwise—may help
with the implementation of quality initiatives and, hopefully,
with the ultimate improvement in patient outcomes.
Public Awareness of the Burden and Impact
of Congenital Heart Defects
While the medical community is beginning to realize the
increasing public health burden and impact of the aging CHD
population, many persons with CHDs remain unaware of the
long-term impact of their disease and the need for lifelong
care.
6 Adolescents often have unrealistic expectations of their
life expectancy and the severity of their cardiac conditions.
54
Educating patients about their disease and the need for
appropriate, lifelong care provided by a healthcare team
knowledgeable in the nuances of these “new” diseases should
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negative public health impact of the diseases.
Public Awareness Campaign
A public awareness campaign emphasizing the need for
lifelong care should address two main populations. First, the
campaign should encourage people currently receiving care
for a CHD to remain in lifelong care, even during periods of
good health. Physicians who treat individuals with CHDs must
become patient educators, emphasizing the need for lifelong
care. Guidelines that highlight the need for continuous care
across the lifespan would help both patients and clinicians.
Second, the campaign should develop a recapture component
designed to reach adolescents and adults with CHDs who
have been lost to care, particularly those with a history of a
moderate or complex lesion.
55 To reach and beneﬁt the
maximum number of individuals, a recapture campaign might
require print media, television advertising, and social media.
56
Care should be taken not to stigmatize individuals with CHDs
and to be sensitive to the complex psychosocial issues of
having a lifelong congenital condition. This could be achieved
through positive “branding” of a lifelong care public aware-
ness campaign as was demonstrated in a recent CDC
campaign to increase physical activity among children.
57
There are several challenges associated with the develop-
ment of a public health awareness campaign. First, CHDs are
a heterogeneous group of congenital anomalies; thus, a
general deﬁnition of CHDs of varying severity should be used
to connect with the largest possible audience. Second, health
literacy and access to care likely varies tremendously
throughout the CHD population; a public awareness campaign
should, therefore, target multiple audiences in a variety of
ways. Third, a campaign of this speciﬁcity and scope will
require considerable funding; multiorganizational collabora-
tion will maximize the effectiveness of the campaign. It is
hoped that knowledge gained through population-based
surveillance and research will inform educational campaigns
targeted to speciﬁc populations and issues.
Educational Materials
Public awareness of the impact and burden of CHDs is not
enough. Patients need to become better educated regarding
their diseases and thus empowered to ensure appropriate,
lifelongcare.Educationalmaterialstargetedtowardthegeneral
public, public health professionals, physicians, schools, and
individuals with CHDs could be made available and accessible
through websites, healthcare provider locations, professional
organizations, and patient groups. Ensuring a variety of
educational materials will enable a broader understanding of
CHDs and reach a wide audience.
Topics of interest may include treatment guidelines (eg, on
neurodevelopmental and psychosocial outcomes) and educa-
tional materials for special populations such as children,
adolescents, adults of various ages, and pregnant women.
CDC and other websites could provide general information to
increase public awareness of CHDs, provide materials for
affected individuals, state the goals of public health research,
identify risk factors and prevention strategies for CHDs and
their comorbidities, and announce when milestones in CHD
prevention and care have been reached.
Future Directions
CHDs are an important public health issue based on their
prevalence, severity, and impact across the lifespan. The
public health science agenda for CHDs can help guide future
surveillance, research, prevention, and communication efforts
to ensure that resources are being directed to address the
most signiﬁcant knowledge gaps affecting the growing
population with CHDs. The overall public health objectives
are to prevent CHDs when possible by better understanding
the causes and implementing successful intervention efforts,
and improve the longer-term outcomes including reducing
mortality, morbidity, and other adverse consequences for all
those with CHDs. Coordinated efforts among federal agen-
cies, professional organizations, advocacy groups, individual
care providers, researchers, and other key stakeholders to
implement this public health science agenda for CHDs could
result in signiﬁcant progress in addressing these CHD public
health objectives.
Acknowledgments
Additional meeting participants (Being listed as a participant does not
imply that the participants or the organizations that they represent
endorse all aspects of this report) are listed in the following: Brian
Armour, PhD, Centers for Disease Control and Prevention, Atlanta,
GA; Scott Baldwin, MD, American Heart Association, Vanderbilt
University School of Medicine, Nashville, TN; Eugene Blackstone, MD,
Cleveland Clinic, Cleveland, OH; Wendy Book, MD, Emory University,
Atlanta, GA; Lorenzo Botto, MD, University of Utah School of
Medicine, Salt Lake City, UT; Coleen Boyle, PhD, MSHyg, Centers
for Disease Control and Prevention, Atlanta, GA; Nakela Cook, MD,
MPH, National Heart, Lung, and Blood Institute, Bethesda, MD; Adolfo
Correa, MD, MPH, PhD, MBA, University of Mississippi Medical
Center, Jackson, MS; Pam Costa, MA, Centers for Disease Control and
Prevention, Atlanta, GA; Curt Daniels, MD, The Ohio State University,
Nationwide Children’s Hospital, Columbus, OH; Charlotte Druschel,
MD, MPH, New York State Department of Health, University of Albany
School of Public Health, Troy, NY; Bruce Gelb, MD, Icahn School of
Medicine at Mount Sinai, New York, NY; Mary George, MD, MSPH,
Centers for Disease Control and Prevention, Atlanta, GA; Suzanne
Gilboa, PhD, Centers for Disease Control and Prevention, Atlanta, GA;
Jill Glidewell, RN, MSN, MPH, Centers for Disease Control and
DOI: 10.1161/JAHA.113.000256 Journal of the American Heart Association 8
Public Health Science Agenda for CHDs Oster et al
S
P
E
C
I
A
L
R
E
P
O
R
TPrevention, Atlanta, GA; Darryl Gray, MD, ScD, Agency for Healthcare
Research and Quality, Rockville, MD; Philip Greenland, MD, North-
western University Feinberg School of Medicine, Chicago, IL; Jeffrey
Jacobs, MD, All Children’s Hospital, Society of Thoracic Surgeons,
Congenital Heart Surgeons Society, St. Petersburg, FL; Kathy Jenkins,
MD, MPH, American College of Cardiology, Children’s Hospital
Boston, Harvard Medical School, Boston, MA; Brian Kogon, MD,
Emory Healthcare, Children’s Healthcare of Atlanta, Atlanta, GA;
Adrienne Kovacs, PhD, University Health Network, Toronto, Toronto,
ON, Canada; Karen Kuehl, MD, MPH, Children’s National Medical
Center, Washington DC; Keila Lopez, MD, MPH, Baylor College of
Medicine, Texas Children’s Hospital, Houston, TX; William Mahle, MD,
American Heart Association, Children’s Healthcare of Atlanta, Atlanta,
GA; Ariane Marelli, MD, MPH, McGill University Health Centre,
Montreal, QC, Canada; Bradley Marino, MD, MPP, MSCE, Cincinnati
Children’s Hospital, Cincinnati, OH; Susan May, Congenital Heart
Public Health Consortium, Cartersville, GA; Brian McCrindle, MD,
MPH, The Hospital for Sick Children, Toronto, ON, Canada; Ninad
Mishra, MD, Centers for Disease Control and Prevention, Atlanta, GA;
Cynthia Moore, MD, PhD, Centers for Disease Control and Prevention,
Atlanta, GA; Jane Newburger, MD, MPH, Children’s Hospital Boston,
Harvard Medical School, Boston, MA; Godfrey Oakley, MD, MSPM,
Rollins School of Public Health, Emory University, Atlanta, GA; Richard
Ohye, MD, C.S. Mott Children’s Hospital, University of Michigan, Ann
Arbor, MI; Richard Olney, MD, MPH, Centers for Disease Control and
Prevention, Atlanta, GA; Morten Olsen, MD, PhD, Aarhus University
Hospital, Denmark; Sara Pasquali, MD, MHS, C.S. Mott Children’s
Hospital, University of Michigan, Ann Arbor, MI; Gail Pearson, MD,
ScD, National Heart, Lung, and Blood Institute, Bethesda, MD; Joseph
Rossano, MD, MS, Children’s Hospital of Philadelphia, Philadelphia,
PA; Karen Stout, MD, University of Washington School of Medicine,
Seattle Children’s Hospital, Seattle, WA; Susan Vanderpool, Mended
Little Hearts, Tulsa, OK; Amy Verstappen, MEd, Adult Congenital Heart
Association, Philadelphia, PA; Richard Wild, MD, JD, MBA, Atlanta
Centers for Medicare and Medicaid Services, Atlanta, GA; and Roberta
Williams, MD, Children’s Hospital Los Angeles, University of Southern
California, Los Angeles, CA.
Sources of Funding
This work was supported in part by an appointment to the
Research Participation Program at the Centers for Disease
Control and Prevention administered by the Oak Ridge
Institute for Science and Education through an interagency
agreement between the US Department of Energy and the
Centers for Disease Control and Prevention.
Disclosures
None.
References
1. Reller MD, Strickland MJ, Riehle-Colarusso T, Mahle WT, Correa A. Prevalence
of congenital heart defects in metropolitan Atlanta, 1998–2005. J Pediatr.
2008;153:807–813.
2. Departments of Labor, Health, and Human Services, and Education and
Related Agencies Appropriations Act, 2012. Calendar No. 178 (S 1599). In:
112th Congress 1st Session (2011–2012). 2012.
3. Connor JA, Gauvreau K, Jenkins KJ. Factors associated with increased
resource utilization for congenital heart disease. Pediatrics. 2005;116:689–
695.
4. Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, Elixson M,
Warnes CA, Webb CL; American Heart Association Council on Cardiovascular
Disease in the Young. Noninherited risk factors and congenital cardiovascular
defects: current knowledge: a scientiﬁc statement from the American Heart
Association Council on Cardiovascular Disease in the Young. Circulation.
2007;115:2995–3014.
5. Marino BS, Lipkin PH, Newburger JW, Peacock G, Gerdes M, Gaynor JW,
Mussatto KA, Uzark K, Goldberg CS, Johnson WH Jr, Li J, Smith SE, Bellinger
DC, Mahle WT; American Heart Association Congenital Heart Defects
Committee of the Council on Cardiovascular Disease in the Young Council
on Cardiovascular Nursing, and Stroke Council. Neurodevelopmental out-
comes in children with congenital heart disease: evaluation and management:
a scientiﬁc statement from the American Heart Association. Circulation.
2012;126:1143–1172.
6. Williams RG, Pearson GD, Barst RJ, Child JS, Del Nido P, Gersony WM, Kuehl
KS, Landzberg MJ, Myerson M, Neish SR, Sahn DJ, Verstappen A, Warnes CA,
Webb CL; National Heart Lung and Blood Institute Working Group on Research
in Adult Congenital Heart Disease. Report of the National Heart, Lung,
and Blood Institute Working Group on research in adult congenital heart
disease. J Am Coll Cardiol. 2006;47:701–707.
7. LastJM.PublicHealthandHumanEcology.Norwalk,CT:Appleton&Lange;1987.
8. Teutsch SM, Churchill RE, eds. Principles and Practice of Public Health
Surveillance. New York: Oxford UP; 1994.
9. Parker SE, Mai CT, Canﬁeld MA, Rickard R, Wang Y, Meyer RE, Anderson P,
Mason CA, Collins JS, Kirby RS, Correa A; NBDPN. Updated National
Birth Prevalence estimates for selected birth defects in the United States,
2004–2006. Birth Defects Res A Clin Mol Teratol. 2010;88:1008–1016.
10. Copeland G, Feldkamp M, Beres LM, Mai CT, Hinton CF, Glidewell J. Newborn
screening for critical congenital heart disease: potential roles of birth defects
surveillance programs—United States, 2010–2011. MMWR Morb Mortal Wkly
Rep. 2012;61:849–853.
11. NBDPN. Major birth defects data from population-based birth defects
surveillance programs in the United States, 2005–2009. Birth Defects Res A
Clin Mol Teratol. 2012;94:S1–S169.
12. Shin M, Besser LM, Siffel C, Kucik JE, Shaw GM, Lu C, Correa A; CAMPSC.
Prevalence of spina biﬁda among children and adolescents in 10 regions in the
United States. Pediatrics. 2010;126:274–279.
13. Kucik JE, Shin M, Siffel C, Marengo L, Correa A; CAMPSC. Trends in survival
among children with down syndrome in 10 regions of the United States.
Pediatrics. 2013;131:E27–E36.
14. Salemi JL, Tanner JP, Kennedy S, Block S, Bailey M, Correia JA, Watkins SM,
Kirby RS. A comparison of two surveillance strategies for selected birth
defects in Florida. Public Health Rep. 2012;127:391–400.
15. Mathews KD, Cunniff C, Kantamneni JR, Ciafaloni E, Miller T, Matthews D, Cwik
V, Druschel C, Miller L, Meaney FJ, Sladky J, Romitti PA. Muscular dystrophy
surveillance tracking and research network (MD STARnet): case deﬁnition
in surveillance for childhood-onset Duchenne/Becker muscular dystrophy.
J Child Neurol. 2010;25:1098–1102.
16. Hoots WK. The registry and surveillance in hemoglobinopathies: improving
the lives of individuals with hemoglobinopathies. Am J Prev Med. 2010;38:
S510–S511.
17. JensenPB,JensenLJ,BrunakS.Miningelectronichealthrecords:towardsbetter
research applications and clinical care. Nat Rev Genet. 2012;13:395–405.
18. Kulich M, Rosenfeld M, Goss CH, Wilmott R. Improved survival among young
patients with cystic ﬁbrosis. J Pediatr. 2003;142:631–636.
19. Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart
disease in the general population: changing prevalence and age distribution.
Circulation. 2007;115:163–172.
20. Marelli A, Gilboa S, Devine O, Kucik J, Lonescu-Lttu R, Oster M,
Riehle-Colarusso T, Correa A, Jenkins K. Estimating the congenital heart
disease population in the United States in 2010—what are the numbers? JA m
Coll Cardiol. 2012;59:E787–E787.
21. Pierpont ME, Basson CT, Benson DW Jr, Gelb BD, Giglia TM, Goldmuntz E,
Mcgee G, Sable CA, Srivastava D, Webb CL; American Heart Association
Congenital Cardiac Defects Committee Council on Cardiovascular Disease in
the Young. Genetic basis for congenital heart defects: current knowledge: a
scientiﬁc statement from the American Heart Association Congenital Cardiac
Defects Committee, Council on Cardiovascular Disease in the Young.
Circulation. 2007;115:3015–3038.
22. Correa A, Gilboa SM, Besser LM, Botto LD, Moore CA, Hobbs CA, Cleves MA,
Riehle-Colarusso TJ, Waller DK, Reece EA. Diabetes mellitus and birth defects.
Am J Obstet Gynecol. 2008;199:237.
DOI: 10.1161/JAHA.113.000256 Journal of the American Heart Association 9
Public Health Science Agenda for CHDs Oster et al
S
P
E
C
I
A
L
R
E
P
O
R
T23. Gilboa SM, Correa A, Botto LD, Rasmussen SA, Waller DK, Hobbs CA,
Cleves MA, Riehle-Colarusso TJ; NBDPS. Association between prepregnancy
body mass index and congenital heart defects. Am J Obstet Gynecol. 2010;
202:51.
24. Oster ME, Riehle-Colarusso T, Correa A. An update on cardiovascular
malformations in congenital rubella syndrome. Birth Defects Res A Clin Mol
Teratol. 2010;88:1–8.
25. Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-
Colarusso T, Honein MA; NBDPS. Maternal treatment with opioid analgesics
and risk for birth defects. Am J Obstet Gynecol. 2011;204:314.
26. Alverson CJ, Strickland MJ, Gilboa SM, Correa A. Maternal smoking and
congenital heart defects in the Baltimore-Washington Infant Study. Pediatrics.
2011;127:E647–E653.
27. Hartman RJ, Rasmussen SA, Botto LD, Riehle-Colarusso T, Martin CL, Cragan
JD, Shin M, Correa A. The contribution of chromosomal abnormalities to
congenital heart defects: a population-based study. Pediatr Cardiol.
2011;32:1147–1157.
28. Hamner HC, Tinker SC, Flores AL, Mulinare J, Weakland AP, Dowling NF.
Modeling fortiﬁcation of corn masa ﬂour with folic acid and the potential
impact on Mexican-American women with lower acculturation. Public Health
Nutr. 2013;16:912–921.
29. Warnes CA, Liberthson R, Danielson GK, Dore A, Harris L, Hoffman JI,
Somerville J, Williams RG, Webb GD. Task force 1: the changing proﬁle of
congenital heart disease in adult life. J Am Coll Cardiol. 2001;37:1170–1175.
30. Ferencz C, Rubin JD, Mccarter RJ, Brenner JI, Neill CA, Perry LW, Hepner SI,
Downing JW. Congenital heart disease: prevalence at livebirth. The Balti-
more-Washington Infant Study. Am J Epidemiol. 1985;121:31–36.
31. Report of the New England Regional Infant Cardiac Program. Pediatrics.
1980;65:375–461.
32. Nadas AS. Report from the joint study on the natural history of congenital
heart defects. IV. Clinical Course. Circulation. 1977;56(Suppl 1):I36–38.
33. Hayes CJ, Gersony WM, Driscoll DJ, Keane JF, Kidd L, O’Fallon WM, Pieroni DR,
Wolfe RR, Weidman WH. Second natural history study of congenital heart
defects. Results of treatment of patients with pulmonary valvar stenosis.
Circulation. 1993;87:I28–I37.
34. Keane JF, Driscoll DJ, Gersony WM, Hayes CJ, Kidd L, O’Fallon WM, Pieroni DR,
Wolfe RR, Weidman WH. Second natural history study of congenital heart
defects. Results of treatment of patients with aortic valvar stenosis.
Circulation. 1993;87:I16–I27.
35. Kidd L, Driscoll DJ, Gersony WM, Hayes CJ, Keane JF, O’Fallon WM, Pieroni DR,
Wolfe RR, Weidman WH. Second natural history study of congenital heart
defects. Results of treatment of patients with ventricular septal defects.
Circulation. 1993;87:I38–I51.
36. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital
heart disease. Circulation. 2007;115:1039–1050.
37. Aﬁlalo J, Therrien J, Pilote L, Ionescu-Ittu R, Martucci G, Marelli AJ. Geriatric
congenital heart disease: burden of disease and predictors of mortality. JA m
Coll Cardiol. 2011;58:1509–1515.
38. Rychik J, Veldtman G, Rand E, Russo P, Rome JJ, Krok K, Goldberg DJ, Cahill AM,
Wells RG. The precarious state of the liver after a Fontan operation: summary of
a multidisciplinary symposium. Pediatr Cardiol. 2012;33:1001–1012.
39. Jenkins KJ, Beekman Iii RH, Bergersen LJ, Everett AD, Forbes TJ, Franklin RC,
Klitzner TS, Krogman ON, Martin GR, Webb CL. Databases for assessing the
outcomes of the treatment of patients with congenital and paediatric cardiac
disease—the perspective of cardiology. Cardiol Young. 2008;18(suppl 2):
116–123.
40. Jacobs ML, Jacobs JP, Franklin RC, Mavroudis C, Lacour-Gayet F, Tchervenkov
CI, Walters H, Bacha EA, Clarke DR, William GAYNOR J, Spray TL, Stellin G, Ebels
T, Maruszewski B, Tobota Z, Kurosawa H, Elliott M. Databases for assessing
the outcomes of the treatment of patients with congenital and paediatric
cardiac disease—the perspective of cardiac surgery. Cardiol Young. 2008;
18(suppl 2):101–115.
41. Larovere JM, Jeffries HE, Sachdeva RC, Rice TB, Wetzel RC, Cooper DS, Bird
GL, Ghanayem NS, Checchia PA, Chang AC, Wessel DL. Databases for
assessing the outcomes of the treatment of patients with congenital and
paediatric cardiac disease—the perspective of critical care. Cardiol Young.
2008;18(suppl 2):130–136.
42. Vener DF, Jacobs JP, Schindler E, Maruszewski B, Andropoulos D. Databases
for assessing the outcomes of the treatment of patients with congenital and
paediatric cardiac disease—the perspective of anaesthesia. Cardiol Young.
2008;18(suppl 2):124–129.
43. Welke KF, Karamlou T, Diggs BS. Databases for assessing the outcomes of the
treatment of patients with congenital and paediatric cardiac disease—a
comparison of administrative and clinical data. Cardiol Young. 2008;18(suppl
2):137–144.
44. Jacobs JP, Haan CK, Edwards FH, Anderson RP, Grover FL, Mayer JE Jr,
Chitwood WR Jr. The rationale for incorporation of HIPAA compliant unique
patient, surgeon, and hospital identiﬁer ﬁelds in the STS database. Ann Thorac
Surg. 2008;86:695–698.
45. Johnson SB, Whitney G, Mcauliffe M, Wang H, Mccreedy E, Rozenblit L, Evans
CC. Using global unique identiﬁers to link autism collections. J Am Med Inform
Assoc. 2010;17:689–695.
46. Strickland MJ, Riehle-Colarusso TJ, Jacobs JP, Reller MD, Mahle WT, Botto LD,
Tolbert PE, Jacobs ML, Lacour-Gayet FG, Tchervenkov CI, Mavroudis C, Correa
A. The importance of nomenclature for congenital cardiac disease: implica-
tions for research and evaluation. Cardiol Young. 2008;18(suppl 2):92–100.
47. Skorton DJ, Garson A Jr, Allen HD, Fox JM, Truesdell SC, Webb GD, Williams
RG. Task force 5: adults with congenital heart disease: access to care. JA m
Coll Cardiol. 2001;37:1193–1198.
48. Verheugt CL, Uiterwaal CS, Van Der Velde ET, Meijboom FJ, Pieper PG,
Sieswerda GT, Plokker HW, Grobbee DE, Mulder BJ. The emerging burden of
hospital admissions of adults with congenital heart disease. Heart. 2010;
96:872–878.
49. Yeung E, Kay J, Roosevelt GE, Brandon M, Yetman AT. Lapse of care as a
predictor for morbidity in adults with congenital heart disease. Int J Cardiol.
2008;125:62–65.
50. Sable C FE, Uzark K, Bjornsen K, Canobbio MM, Connolly HM, Graham TP,
Gurvitz MZ, Kovacs A, Meadows AK, Reid GJ, Reiss JG, Rosenbaum KN,
Sagerman PJ, Saidi A, Schonberg R, Shah S, Tong E, Williams RG; American
Heart Association Congenital Heart Defects Committee of the Council on
Cardiovascular Disease in the Young, Council on Cardiovascular Nursing,
Council on Clinical Cardiology, Council on Peripheral Vascular Disease. Best
practices in managing transition to adulthood for adolescents with congenital
heart disease: the transition process and medical and psychosocial issues: a
scientiﬁc statement from the American Heart Association. Circulation. 2011;
123:1454–1485.
51. IOM. Better Care at Lower Cost: the Path to Continuously Learning Health Care
in America. Washington, DC: The National Academies Press; 2012.
52. Pasquali SK, Ohye RG, Lu M, Kaltman J, Caldarone CA, Pizarro C,
Dunbar-Masterson C, Gaynor JW, Jacobs JP, Kaza AK, Newburger J, Rhodes
JF, Scheurer M, Silver E, Sleeper LA, Tabbutt S, Tweddell J, Uzark K, Wells W,
Mahle WT, Pearson GD; Pediatric Heart Network Investigators. Variation in
perioperative care across centers for infants undergoing the Norwood
procedure. J Thorac Cardiovasc Surg. 2012;144:915–921.
53. Kugler JD, Beekman Iii RH, Rosenthal GL, Jenkins KJ, Klitzner TS, Martin GR,
Neish SR, Lannon C. Development of a pediatric cardiology quality improve-
ment collaborative: from inception to implementation. From the Joint Council
on Congenital Heart Disease Quality Improvement Task Force. Congenit Heart
Dis. 2009;4:318–328.
54. Reid GJ, Webb GD, Barzel M, Mccrindle BW, Irvine MJ, Siu SC. Estimates of
life expectancy by adolescents and young adults with congenital heart
disease. J Am Coll Cardiol. 2006;48:349–355.
55. Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA, Del
Nido P, Fasules JW, Graham TP Jr, Hijazi ZM, Hunt SA, King ME, Landzberg MJ,
Miner PD, Radford MJ, Walsh EP, Webb GD. ACC/AHA 2008 Guidelines for the
Managementof Adults with Congenital HeartDisease: aReport of the American
College of Cardiology/American Heart Association Task Force on Practice
Guidelines (writing committee to develop guidelines on the management of
adults with congenital heart disease). Circulation. 2008;118:E714–E833.
56. Petrella RJ, Speechley M, Kleinstiver PW, Ruddy T. Impact of a social marketing
media campaign on public awareness of hypertension. Am J Hypertens. 2005;
18:270–275.
57. Asbury LD, Wong FL, Price SM, Nolin MJ. The VERB campaign: applying a
branding strategy in public health. Am J Prev Med. 2008;34:S183–S187.
Key Words: heart defects ￿ congenital ￿ epidemiology ￿
population ￿ prevention ￿ risk factors
DOI: 10.1161/JAHA.113.000256 Journal of the American Heart Association 10
Public Health Science Agenda for CHDs Oster et al
S
P
E
C
I
A
L
R
E
P
O
R
T